Fetal echocardiography is not only used to detect congenital heart disease but also to monitor fetuses, especially those with different pathologies

Oskar Sylwestrzak1, 2, Iwona Strzelecka2, Maciej Słodki1, 3, Maria Respondek-Liberska1, 2

1Department of Prenatal Cardiology, Polish Mother’s Memorial Hospital Research Institute, Łódź, Poland
2Department of Diagnosis and Prevention of Fetal Malformations, Medical University of Łódź, Łódź, Poland
3Faculty of Health Sciences, The Mazovian State University, Płock, Poland

We have read with great interest the article by Buczyński et al. [1] entitled “Life-threatening congenital hydropericardium in a newborn with Down syndrome, transient abnormal myelopoiesis, Hirschsprung disease, and a ventricular septal defect”. We would like to congratulate the authors on detecting prenatally a congenital heart defect and on their effort to publish such an interesting case. It is worth commending the authors’ clinical experience with successful neonatal pericardial drainage. On the other hand, we would like to point out that some procedures described as “urgent” could have been predicted and “planned”.

The authors presented the case of a neonate with prenatally diagnosed ventricular septal defect (VSD) with hydropericardium, who was delivered by Cesarean section at 37 weeks of gestation. Unfortunately, the manuscript lacks basic data, as mentioned below: gestational age at diagnosis of the congenital heart defect, more detailed description of fetal cardiovascular function during gestation, number of fetal echocardiographic examinations and strategy of fetal monitoring, fetal cardiovascular physiology changes with gestation, and indication for Cesarean section. As recommended by the Polish Society of Prenatal Cardiology, every congenital heart defect detected prenatally should be monitored using fetal echocardiography [2]. Contemporary fetal echocardiography focuses not only on the analysis of the heart structure but also on the assessment of its function. The evaluation of the fetal heart function is most valuable in the third trimester of pregnancy, just before delivery [2]. If the fetus, especially with a congenital heart defect or functional anomalies, is monitored for several weeks using fetal echocardiography, and the last examination is performed shortly before delivery, the condition of the newborn in the first hours and days of extrauterine life can be reliably predicted [2, 3]. Life-threatening congenital hydropericardium is an extremely rare condition and may be caused by infection, cardiac masses like tumors, and other chronic diseases, as mentioned by the authors. In each case, the cause of hydropericardium should be thoroughly searched. Hydropericardium could also occur along with genetic disorder such as Down syndrome. More detailed serial echocardiographic monitoring could have also had additional advantages — abnormal results of echocardiographic examination could be the indication for expanded “genetic ultrasonography”, and other signs (VSD was noticed) of trisomy 21 could have been detected earlier. Any congenital heart defect detected prenatally should be closely examined, even during the COVID-19 pandemic [4]. In the current era of dynamic development of prenatal cardiology [5], the absence of at least two echocardiographic examinations in the case of timely prenatal detection of a congenital heart defect should be highlighted and reconsidered next time. Probably, we should pay more attention to the prenatal period of human life. Maybe in this case the postnatal tachycardia, central cyanosis, and transient hypoxia could have been avoided.
**Article information**

**Conflict of interest:** None declared.

**Funding:** None.

**Open access:** This article is available in open access under Creative Common Attribution-Non-Commercial-No Derivatives 4.0 International (CC BY-NC-ND 4.0) license, allowing to download articles and share them with others as long as they credit the authors and the publisher, but without permission to change them in any way or use them commercially. For commercial use, please contact the journal office at kardiologiapolska@ptkardio.pl.

**REFERENCES**


